<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683800</url>
  </required_header>
  <id_info>
    <org_study_id>3151A2-3353</org_study_id>
    <secondary_id>B2061011</secondary_id>
    <nct_id>NCT00683800</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety And Efficacy Of DVS SR For The Treatment Of Vasomotor Symptoms Associated With Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate
      (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor
      Symptoms (VMS) in menopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) Events</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>Adjudicated ischemic cardiovascular events were a composite of: a) Coronary Heart Disease (CHD)-related death; b) New Myocardial Infarction (MI) (non-procedure-related MI); c) Documented new onset of unstable angina requiring hospitalization; d) Unscheduled coronary revascularization procedures (percutaneous coronary intervention) or bypass grafting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Minimal Clinically Meaningful Decrease in the Average Daily Number of Hot Flushes</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>A mean decrease from baseline of at least 5.35 moderate to severe hot flushes at week 12 in the participants was considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 75% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to the First Day of 3 Consecutive Days of at Least 50% Reduction in Hot Flushes</measure>
    <time_frame>Week 12</time_frame>
    <description>Time to response was defined as the time-to-first 50% reduction in the average daily number of moderate to severe hot flushes over 3 consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adjusted Means in the Number of Moderate and Severe Hot Flushes at Month 6 and Month 12</measure>
    <time_frame>Baseline, Month 6 and Month 12</time_frame>
    <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. Adjusted mean was calculated by using change from baseline as response variable, treatment as factor, and baseline as covariate using the observed cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adjusted Means in the Hot Flush Severity Score at Month 6 and Month 12</measure>
    <time_frame>Baseline, Month 6 and Month 12</time_frame>
    <description>Severity: mild (heat sensation without sweating); moderate (heat sensation with sweating; able to continue activity); severe (heat sensation with sweating; causing cessation of activity). Average daily severity of hot flushes= (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). Days with no hot flushes: severity score=0. As it was derived from count data, there was no maximum; minimum score=0; higher values= worse outcomes. Adjusted mean: calculated using change from baseline=response variable, treatment=factor and baseline=covariate using observed cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>PGI-C score was intended to assess the study participant's perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2186</enrollment>
  <condition>Vasomotor Symptoms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>desvenlafaxine succinate (DVS) SR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desvenlafaxine succinate (DVS) SR</intervention_name>
    <description>Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy, postmenopausal women who seek treatment for hot flushes

          -  Body Mass Index (BMI) less than or equal to 34 kg/m^2

        Exclusion Criteria:

          -  Hypersensitivity to Venlafaxine

          -  Myocardial infarction an/or unstable angina within 6 months of screening

          -  History of seizure disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jamestown</city>
        <state>North Dakota</state>
        <zip>58401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112-4481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507-1411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V4A 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Antigonish</city>
        <state>Nova Scotia</state>
        <zip>B2G 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <zip>N0N 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9A 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>L'Ancienne-Lorette</city>
        <state>Quebec</state>
        <zip>G2E 2X1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Janvier</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shawinigan</city>
        <state>Quebec</state>
        <zip>G9N 2H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3151A2-3353&amp;StudyName=Study%20Evaluating%20The%20Safety%20And%20Efficacy%20Of%20Desvenlafaxine%20Succinate%20For%20Vasomotor%20Symptoms%20In%20Menopausal%20Women</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <results_first_submitted>April 21, 2011</results_first_submitted>
  <results_first_submitted_qc>July 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2011</results_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc</organization>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Hot Flush</keyword>
  <keyword>Hot Flash</keyword>
  <keyword>Desvenlafaxine succinate Sustained Release</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 3784 participants were screened, of which 1598 participants were screen failures and 2186 participants were randomly assigned to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DVS SR 100 mg</title>
          <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1101"/>
                <participants group_id="P2" count="1085"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="1066"/>
                <participants group_id="P2" count="1052"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="669"/>
                <participants group_id="P2" count="719"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="366"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, not treated</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DVS SR 100 mg</title>
          <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1066"/>
            <count group_id="B2" value="1052"/>
            <count group_id="B3" value="2118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.95" spread="4.90"/>
                    <measurement group_id="B2" value="53.59" spread="4.91"/>
                    <measurement group_id="B3" value="53.77" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1066"/>
                    <measurement group_id="B2" value="1052"/>
                    <measurement group_id="B3" value="2118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily number of moderate and severe hot flushes</title>
          <description>Average daily number of moderate and severe hot flushes was calculated as the sum of number of moderate and severe hot flushes on each day divided by number of days with data. Moderate: sensation of heat with sweating; able to continue activity; and severe: sensation of heat with sweating; causing cessation of activity. Participants analysed were 184 and 181 for DVS SR 100 mg group and placebo group, respectively.</description>
          <units>Hot Flushes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.67" spread="5.62"/>
                    <measurement group_id="B2" value="11.91" spread="5.71"/>
                    <measurement group_id="B3" value="11.79" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily severity score of hot flushes</title>
          <description>Severity: mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). Average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For days with no hot flushes, severity score was set as 0. As this was derived from count data, there was no maximum; minimum score was 0; the higher values showed worse outcomes. n=184 (DVS SR 100 mg group); n=181 (placebo group).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.36" spread="0.34"/>
                    <measurement group_id="B2" value="2.39" spread="0.35"/>
                    <measurement group_id="B3" value="2.37" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4</title>
        <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Modified Intent-to-Treat(MITT) population: Participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks. Last observation carried forward (LOCF) method was used. 1 participant in each group did not have data till Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4</title>
          <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
          <population>Modified Intent-to-Treat(MITT) population: Participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks. Last observation carried forward (LOCF) method was used. 1 participant in each group did not have data till Week 4.</population>
          <units>Hot Flushes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.52" spread="0.33"/>
                    <measurement group_id="O2" value="-3.64" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>-1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12</title>
        <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12</title>
          <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
          <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
          <units>Hot Flushes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.31" spread="0.35"/>
                    <measurement group_id="O2" value="-4.52" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>-1.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4</title>
        <description>Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using LOCF method. 1 participant in each group did not have data till Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4</title>
          <description>Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.</description>
          <population>MITT population: All participants randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using LOCF method. 1 participant in each group did not have data till Week 4.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.04"/>
                    <measurement group_id="O2" value="-0.19" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12</title>
        <description>Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12</title>
          <description>Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.</description>
          <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.05"/>
                    <measurement group_id="O2" value="-0.28" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) Events</title>
        <description>Adjudicated ischemic cardiovascular events were a composite of: a) Coronary Heart Disease (CHD)-related death; b) New Myocardial Infarction (MI) (non-procedure-related MI); c) Documented new onset of unstable angina requiring hospitalization; d) Unscheduled coronary revascularization procedures (percutaneous coronary intervention) or bypass grafting.</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) Events</title>
          <description>Adjudicated ischemic cardiovascular events were a composite of: a) Coronary Heart Disease (CHD)-related death; b) New Myocardial Infarction (MI) (non-procedure-related MI); c) Documented new onset of unstable angina requiring hospitalization; d) Unscheduled coronary revascularization procedures (percutaneous coronary intervention) or bypass grafting.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ischemic CV event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHD related death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Onset of Unstable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Coronary Revascularization Procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Excess risk of DVS SR 100 mg over placebo per 1000 woman-years of exposure, defined as the difference in the exposure adjusted rates between the treatment groups, was obtained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Wald Formula</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.86</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>The 90% CI for excess risk was obtained using the Wald Formula.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Minimal Clinically Meaningful Decrease in the Average Daily Number of Hot Flushes</title>
        <description>A mean decrease from baseline of at least 5.35 moderate to severe hot flushes at week 12 in the participants was considered clinically meaningful.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Minimal Clinically Meaningful Decrease in the Average Daily Number of Hot Flushes</title>
          <description>A mean decrease from baseline of at least 5.35 moderate to severe hot flushes at week 12 in the participants was considered clinically meaningful.</description>
          <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of participants achieving a response as defined by minimal clinically important difference (MCID) at week 12 was compared between DVS and placebo treatment groups with a Cochran-Mantel-Haenszel test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes</title>
        <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes</title>
          <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
          <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.47"/>
                    <measurement group_id="O2" value="28.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.93"/>
                    <measurement group_id="O2" value="44.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of participants achieving at least 50% hot flush reduction from baseline at 4-week was compared between DVS and placebo treatment groups with a logistic regression model with treatment as factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.24</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of participants achieving at least 50% hot flush reduction from baseline at 12-week was compared between DVS and placebo treatment groups with a logistic regression model with treatment as factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 75% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes</title>
        <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 75% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes</title>
          <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.</description>
          <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy. Assessment was done using last observation carried forward (LOCF) method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.79"/>
                    <measurement group_id="O2" value="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.30"/>
                    <measurement group_id="O2" value="18.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of participants achieving at least 75% hot flush reduction from baseline at 4-week was compared between DVS and placebo treatment groups with a logistic regression model with treatment as factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.47</ci_lower_limit>
            <ci_upper_limit>7.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of participants achieving at least 75% hot flush reduction from baseline at 12-week was compared between DVS and placebo treatment groups with a logistic regression model with treatment as factor and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to the First Day of 3 Consecutive Days of at Least 50% Reduction in Hot Flushes</title>
        <description>Time to response was defined as the time-to-first 50% reduction in the average daily number of moderate to severe hot flushes over 3 consecutive days.</description>
        <time_frame>Week 12</time_frame>
        <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to the First Day of 3 Consecutive Days of at Least 50% Reduction in Hot Flushes</title>
          <description>Time to response was defined as the time-to-first 50% reduction in the average daily number of moderate to severe hot flushes over 3 consecutive days.</description>
          <population>MITT population included all participants who were randomized into efficacy substudy, had at least 1 dose of study drug, had vasomotor symptoms recorded on at least 1 day of baseline period and at least 1 day of on-therapy period during initial 12 weeks of therapy.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="10.0" upper_limit="18.0"/>
                    <measurement group_id="O2" value="48.0" lower_limit="32.0" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A log-rank test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adjusted Means in the Number of Moderate and Severe Hot Flushes at Month 6 and Month 12</title>
        <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. Adjusted mean was calculated by using change from baseline as response variable, treatment as factor, and baseline as covariate using the observed cases.</description>
        <time_frame>Baseline, Month 6 and Month 12</time_frame>
        <population>MITT participants of the efficacy sub-study population who had non-missing average daily number of moderate and severe hot flushes. The assessment was done using observed values. The 'n' is signifying those participants who received study drug and were evaluated for this measure at the time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adjusted Means in the Number of Moderate and Severe Hot Flushes at Month 6 and Month 12</title>
          <description>The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity. Adjusted mean was calculated by using change from baseline as response variable, treatment as factor, and baseline as covariate using the observed cases.</description>
          <population>MITT participants of the efficacy sub-study population who had non-missing average daily number of moderate and severe hot flushes. The assessment was done using observed values. The 'n' is signifying those participants who received study drug and were evaluated for this measure at the time point for each group respectively.</population>
          <units>Hot Flushes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n= 125, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.65" spread="0.37"/>
                    <measurement group_id="O2" value="-6.61" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n= 112, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.98" spread="0.46"/>
                    <measurement group_id="O2" value="-5.17" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided). (At month 6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.07</ci_lower_limit>
            <ci_upper_limit>-1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided). (At month 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.12</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adjusted Means in the Hot Flush Severity Score at Month 6 and Month 12</title>
        <description>Severity: mild (heat sensation without sweating); moderate (heat sensation with sweating; able to continue activity); severe (heat sensation with sweating; causing cessation of activity). Average daily severity of hot flushes= (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). Days with no hot flushes: severity score=0. As it was derived from count data, there was no maximum; minimum score=0; higher values= worse outcomes. Adjusted mean: calculated using change from baseline=response variable, treatment=factor and baseline=covariate using observed cases.</description>
        <time_frame>Baseline, Month 6 and Month 12</time_frame>
        <population>MITT participants of the efficacy sub-study population who had non-missing average daily number of moderate and severe hot flushes. The assessment was done using observed values. The 'n' is signifying those participants who received study drug and were evaluated for this measure at the time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adjusted Means in the Hot Flush Severity Score at Month 6 and Month 12</title>
          <description>Severity: mild (heat sensation without sweating); moderate (heat sensation with sweating; able to continue activity); severe (heat sensation with sweating; causing cessation of activity). Average daily severity of hot flushes= (1*Number of mild+2*Number of moderate+3*Number of severe)/(Total number of hot flushes). Days with no hot flushes: severity score=0. As it was derived from count data, there was no maximum; minimum score=0; higher values= worse outcomes. Adjusted mean: calculated using change from baseline=response variable, treatment=factor and baseline=covariate using observed cases.</description>
          <population>MITT participants of the efficacy sub-study population who had non-missing average daily number of moderate and severe hot flushes. The assessment was done using observed values. The 'n' is signifying those participants who received study drug and were evaluated for this measure at the time point for each group respectively.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n= 125, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.07"/>
                    <measurement group_id="O2" value="-0.56" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n= 112, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.07"/>
                    <measurement group_id="O2" value="-0.45" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided). (At month 6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance with treatment as factor and baseline value as a covariate was used to compare DVS SR 100 mg with matching placebo. The comparison was performed at significance level of p=0.05 (two sided). (At month 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Week 12</title>
        <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy Greene Climacteric Scale (GCS) assessment or at least 1 on therapy Patient Global Impression (PGI) assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Week 12</title>
          <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy Greene Climacteric Scale (GCS) assessment or at least 1 on therapy Patient Global Impression (PGI) assessment.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="964"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.48" spread="0.28"/>
                    <measurement group_id="O2" value="22.04" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Anxiety Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" spread="0.10"/>
                    <measurement group_id="O2" value="6.36" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Depression Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="0.10"/>
                    <measurement group_id="O2" value="4.84" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Sexual Dysfunction Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.03"/>
                    <measurement group_id="O2" value="1.65" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Psychological Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="0.18"/>
                    <measurement group_id="O2" value="11.19" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Somatic Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" spread="0.11"/>
                    <measurement group_id="O2" value="4.21" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Vasomotor Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="0.04"/>
                    <measurement group_id="O2" value="4.99" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.18" spread="0.25"/>
                    <measurement group_id="O2" value="-6.84" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Anxiety Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.09"/>
                    <measurement group_id="O2" value="-2.06" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Depression Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="0.08"/>
                    <measurement group_id="O2" value="-1.55" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Sexual Dysfunction Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.03"/>
                    <measurement group_id="O2" value="-0.36" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Psychological Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.04" spread="0.15"/>
                    <measurement group_id="O2" value="-3.62" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Somatic Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.09"/>
                    <measurement group_id="O2" value="-1.02" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Vasomotor Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="0.05"/>
                    <measurement group_id="O2" value="-1.85" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Total score was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.05</ci_lower_limit>
            <ci_upper_limit>-1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Anxiety scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Depression scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Sexual Dysfunction scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Psychological scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 was outcome variable, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>-1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Somatic scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Week 12: Change from baseline of the GCS Vasomotor scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 6</title>
        <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 6</title>
          <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="796"/>
                <count group_id="O2" value="836"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.84" spread="0.25"/>
                    <measurement group_id="O2" value="-7.97" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.06" spread="0.09"/>
                    <measurement group_id="O2" value="-2.41" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="0.08"/>
                    <measurement group_id="O2" value="-1.77" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.03"/>
                    <measurement group_id="O2" value="-0.41" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.39" spread="0.15"/>
                    <measurement group_id="O2" value="-4.15" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="0.08"/>
                    <measurement group_id="O2" value="-1.31" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasomotor Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="0.06"/>
                    <measurement group_id="O2" value="-2.14" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Total score was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>-1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Anxiety scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Depression scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Sexual Dysfunction scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Psychological scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Somatic scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 6: Change from baseline of the GCS Vasomotor scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6, and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 12</title>
        <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 12</title>
          <description>GCS: a 21 item evaluation of symptoms which asked participants how bothered they were with particular symptom at the moment. Each item was scored as 0 = Not at all, 1 = A little, 2 = Quite a bit, and 3 = Extremely. A total score was derived from the sum of the 21 items (range 0-63). GCS was also used to generate 6 individual scores (psychological symptoms [range 0-33], anxiety [range 0-18], depression [range 0-15], somatic symptoms [range 0-21], vasomotor symptoms [range 0-6], and sexual dysfunction [range 0-3]). A decrease in the total climacteric score indicated an improvement in symptoms.</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="673"/>
                <count group_id="O2" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.60" spread="0.26"/>
                    <measurement group_id="O2" value="-8.89" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="0.09"/>
                    <measurement group_id="O2" value="-2.69" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.66" spread="0.08"/>
                    <measurement group_id="O2" value="-2.04" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.03"/>
                    <measurement group_id="O2" value="-0.43" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.88" spread="0.16"/>
                    <measurement group_id="O2" value="-4.70" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="0.09"/>
                    <measurement group_id="O2" value="-1.61" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasomotor Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="0.06"/>
                    <measurement group_id="O2" value="-2.19" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Total score was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.42</ci_lower_limit>
            <ci_upper_limit>-1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Anxiety scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Depression scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Sexual Dysfunction scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Psychological scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>-0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Somatic scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.865</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Month 12: Change from baseline of the GCS Vasomotor scale subscore was analyzed using a Mixed-effects model repeated measures (MMRM), for which changes from baseline at week 12, month 6 and month 12 were outcome variables, with treatment, week, and interaction between treatment and week as fixed effects with participant as a random effect, and with the baseline score as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Week 12</title>
        <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
        <time_frame>Week 12</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Week 12</title>
          <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="961"/>
                <count group_id="O2" value="982"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 6</title>
        <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
        <time_frame>Month 6</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 6</title>
          <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="963"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 12</title>
        <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
        <time_frame>Month 12</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 12</title>
          <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="963"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Week 12</title>
        <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
        <time_frame>Week 12</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Week 12</title>
          <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
          <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 6</title>
        <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
        <time_frame>Month 6</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 6</title>
          <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
          <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 12</title>
        <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
        <time_frame>Month 12</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 12</title>
          <description>PGI-R scale was intended to assess the study participant's perception of symptoms. Participants were requested to identify the severity of their hot flush symptoms. It was a 5-scale which ranged from 1 (None) to 5 (Severe).</description>
          <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Week 12</title>
        <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
        <time_frame>Week 12</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Week 12</title>
          <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="962"/>
                <count group_id="O2" value="983"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6= Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7= Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 6</title>
        <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
        <time_frame>Month 6</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 6</title>
          <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="963"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6= Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7= Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 12</title>
        <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
        <time_frame>Month 12</time_frame>
        <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 12</title>
          <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
          <population>Main study efficacy population included all participants who were randomized; had at least 1 dose of study medication; and had a baseline and at least 1 on therapy GCS assessment or at least 1 on therapy PGI assessment. Assessment was done using LOCF method.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="963"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6= Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7= Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Week 12</title>
        <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
        <time_frame>Week 12</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Week 12</title>
          <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
          <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6= Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7= Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 6</title>
        <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
        <time_frame>Month 6</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 6</title>
          <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
          <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6= Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7= Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 12</title>
        <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
        <time_frame>Month 12</time_frame>
        <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 12</title>
          <description>PGI-C score was intended to assess the study participants perception of changes in hot flushes. It was 7-point scale which ranged from 1 (Very Much Improved) to 7 (Very Much Worse).</description>
          <population>MITT population: All participants randomized into efficacy substudy; at least 1 dose of study drug, vasomotor symptoms recorded on at least 1 day of baseline period and 1 day of on-therapy period during initial 12 weeks of therapy. LOCF method was used. Participants analyzed included those who were evaluated for this particular scale.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1= Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4= No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6= Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7= Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cochran-Mantel-Haenszel row mean score test was used to compare the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adjudicated Cerebrovascular Events - Any Stroke</title>
        <description>Adjudicated cerebrovascular events were identified using Standardized MedDRA Query (SMQ), for central nervous system haemorrhages and cerebrovascular conditions. Primary assessments included: 1) definite stroke, 2) probable stroke, 3) probable transient ischemic attack (TIA), and 4) no stroke or TIA.</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Cerebrovascular Events - Any Stroke</title>
          <description>Adjudicated cerebrovascular events were identified using Standardized MedDRA Query (SMQ), for central nervous system haemorrhages and cerebrovascular conditions. Primary assessments included: 1) definite stroke, 2) probable stroke, 3) probable transient ischemic attack (TIA), and 4) no stroke or TIA.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Stroke (Definite or Probable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Excess risk over placebo of DVS SR 100 mg per 1000 woman-years of exposure, defined as the difference in the exposure adjusted rates between the treatment groups, was obtained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Wald Formula</param_type>
            <param_value>1.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>The 90% CI for excess risk is obtained using the Wald Formula.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adjudicated Cerebrovascular Events - Probable TIA</title>
        <description>Adjudicated cerebrovascular events were identified using Standardized MedDRA Query (SMQ), for central nervous system haemorrhages and cerebrovascular conditions. Primary assessments included: 1) definite stroke, 2) probable stroke, 3) probable transient ischemic attack (TIA), and 4) no stroke or TIA.</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Cerebrovascular Events - Probable TIA</title>
          <description>Adjudicated cerebrovascular events were identified using Standardized MedDRA Query (SMQ), for central nervous system haemorrhages and cerebrovascular conditions. Primary assessments included: 1) definite stroke, 2) probable stroke, 3) probable transient ischemic attack (TIA), and 4) no stroke or TIA.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Ischemic Heart Disease</title>
        <description>Potential ischaemic cardiac events were identified using the Standardized MedDRA Query (SMQ) &quot;Ischemic Heart Disease&quot;.</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemic Heart Disease</title>
          <description>Potential ischaemic cardiac events were identified using the Standardized MedDRA Query (SMQ) &quot;Ischemic Heart Disease&quot;.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Excess risk over placebo of DVS SR 100 mg per 1000 woman-years of exposure, defined as the difference in the exposure adjusted rates between the treatment groups, was obtained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Wald Formula</param_type>
            <param_value>2.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.08</ci_lower_limit>
            <ci_upper_limit>6.71</ci_upper_limit>
            <estimate_desc>The 90% CI for excess risk is obtained using the Wald Formula.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Hepatic Events</title>
        <description>Hepatic events were defined as incidence of increased Liver Function Test (AST [aspartate aminotransferase] or ALT [alanine aminotransferase]) levels greater than 5 times the ULN (upper limit of normal).</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 100 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatic Events</title>
          <description>Hepatic events were defined as incidence of increased Liver Function Test (AST [aspartate aminotransferase] or ALT [alanine aminotransferase]) levels greater than 5 times the ULN (upper limit of normal).</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Excess risk over placebo of DVS SR 100 mg per 1000 woman-years of exposure, defined as the difference in the exposure adjusted rates between the treatment groups, was obtained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Wald Formula</param_type>
            <param_value>0.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.51</ci_lower_limit>
            <ci_upper_limit>3.67</ci_upper_limit>
            <estimate_desc>The 90% CI for excess risk is obtained using the Wald Formula.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>DVS SR 100 mg</title>
          <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo tablets daily until Day 365 or early withdrawal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Narrow anterior chamber angle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Drug therapeutic incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dermatofibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="941" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="872" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Splenic granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pulmonary valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Right atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Keratosis follicular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mixed hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Conductive deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear canal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Altered visual depth perception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eyelid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Narrow anterior chamber angle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Night blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pinguecula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Presbyopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pupil fixed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Retinal aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Retinopathy hypertensive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Scleral hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitreous degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gingival erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gingival ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Polyp colorectal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Salivary gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tongue dry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tooth discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Implant site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rebound effect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Therapeutic response unexpected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vestibulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Allergy to chemicals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Allergy to plants</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>House dust allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anal fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ear infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Infected sebaceous cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaginal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Viral labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulval cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Animal scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sciatic nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Splinter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Superficial injury of eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vascular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Venomous bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulva injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Whiplash injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Autoantibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Biopsy breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR prolongation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave amplitude decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Heart sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mammogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thyroid function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Total cholesterol/HDL ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tuberculin test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Very low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitamin B12 decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>White blood cells urine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Food craving</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint crepitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ligamentitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Neck deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nodule on extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eye naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lipoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Circadian rhythm sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Decreased vibratory sense</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Exertional headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Head titubation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="332" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sleep phase rhythm disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anhedonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anorgasmia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Change in sustained attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Decreased interest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Derealisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Disturbance in sexual arousal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Feelings of worthlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Frustration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Impatience</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Intentional drug misuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Logorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Obsessive-compulsive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Orgasm abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Orgasmic sensation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sleep talking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sleep terror</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Terminal insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Costovertebral angle tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ketonuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nephrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Residual urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Trigonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urethral caruncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urethral prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast engorgement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervical discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Coital bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Genital discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lactation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pelvic discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Premenstrual syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine cervix stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vaginal stricture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulva cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvar erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Laryngeal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nasal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Acne cystic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Campbell de Morgan spots</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Dyshidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Keloid scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Sebaceous hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Subcutaneous nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Trichorrhexis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Ex-tobacco user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Stress at work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post procedural drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1052"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>GCS scales were analyzed only for main study efficacy population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

